Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine prophylaxis for COVID-19 in high-risk healthcare workers
ACTRN12620000501943Phase 3Recruiting
- Sponsor
- WEHI
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19), sponsored by WEHI. Primary endpoint: Incidence of COVID-19. Started May 2020; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000501943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000501943.